Introduction
IL-10 inhibits alloantigen-induced T cell proliferation and allospecific cytotoxic T cell generation ( 1 ). IL-10 also inhibits macrophage-dependent, antigen-specific T cell proliferation and macrophage-dependent production of cytokines by T cells (2, 3) . These findings suggest a role for IL-10 as a potential agent for prolongation of allograft survival and also for treatment of T cell-mediated autoimmune diseases, such as type I diabetes and multiple sclerosis (4) . The in vivo effects of IL-10 have been studied indirectly in mice with anti-IL-10 antibody administration that resulted in increased levels of IFN-y and depletion of peritoneal Ly-1 B cells (5) . Furthermore, systemic administration of IL-10 inhibits TNF-a release in experimental endotoxemia (6, 7) . However, the immunosuppressive effects of IL-10 in vivo have not been addressed directly despite broad interests in the clinical use of this cytokine, partly because of lack of suitable animal models.
In this report, we investigated the in vivo effects of murine IL-10 on immunological responses using transgenic mice expressing IL-10 in pancreatic ,B cells (Ins-IL-10 mice).' IL-10-transgenic mice have inflammatory lesions surrounding pancreatic islets; however, the islets remain intact and the mice are normoglycemic, indicating that the inflammatory cells are not destructive to the islets (8) . This result is not inconsistent with the immunosuppressive effects ofIL-1O observed in vitro, leading us to perform functional studies in vivo. To address the potential of IL-10 to inhibit or delay allograft rejection, we grafted fetal pancreata or adult islets from Ins-IL-10 mice into MHC-incompatible mice. To test the ability ofIL-IO to modify the autoimmune response, we crossed Ins-IL-10 mice with transgenic mice expressing lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP) or nucleoprotein (NP) antigen in pancreatic ,B cells (RIP-LCMV-GP and RIP-LCMV-NP) (9) . RIP-LCMV-GP and RIP-LCMV-NP mice have normal phenotypes but develop autoimmune diabetes after LCMV infection. Double transgenic mice were infected with LCMV, and the prevalence and onset of diabetes were compared to those in single transgenic littermates.
We in Ins-IL-IO mice embryos was tested with PCR amplification ofgenomic DNA. The pancreata from nontransgenic littermate embryos were used for control grafts. Fetal pancreata were transplanted under the kidney capsule of male allogeneic C57BL/6 mice (H-2b) and control BALB/c mice (H-2d) (Fig. 1 A) . Isolation ofislets. Pancreatic islets were isolated from 2-6-mo-old Ins-IL-10 mice. We used two transgenic lines as islet donors, each having similar expression levels and histopathology. The pancreata were digested with collagenase P (Boehringer Mannheim Corp., Indianapolis, IN) as described (10). All islets were cultured for 3-7 d in RPMI 1640 supplemented with 20 mM Hepes, 300,gg/ml L-glutamine, 100 U/ml penicillin, 100 gg/ml streptomycin, and 10% FCS. The isolated cultured islets appeared circumscribed and free of any detectable associated lymphocyte aggregates. 200 islets were grafted under the kidney capsule of male C57BL/6 mice, BALB/c mice, and congenic BALB.H-2k mice (H-2k). Islets from BALB/c mice served as controls.
In situ hybridization. Grafted tissue was dissected, fixed in zinc formalin, and embedded in paraffin. E18 fetal pancreata and adult pancreata were also embedded. Sections were deparaffinized and prehybridized for 4 h at 42°C in a buffer comprising 50% formamide, 0.3 M NaCl, 20 mM Tris, pH 8.0, 5 mM EDTA, I X Denhardt's solution, 10% dextran sulfate, and 10 mM dithiothreitol. Hybridization was done for 16 h at 42°C in a humidified chamber, followed by washing, dehydration, and drying. Antisense and sense RNA probes were prepared by in vitro transcription ofa linearized plasmid containing IL-10 cDNA, using 35S-labeled UTP. Sections were covered with emulsion (NTB2; Kodak, Rochester, NY) and developed after 1-2 wk.
Production ofIL-IO by transgenic islets. Pancreatic islets were isolated from two transgenic mice and two nontransgenic mice as de- gg/ml L-glutamine, 100 U/ml penicillin, 100 ,g/ml streptomycin, and 10% FCS. The IL-10 production between day 1 and day 5 of culture was measured. The glucose level in the culture medium was 207, 21 1, and 202 mg/dl on day 0, day 1, and day 5 (Glucometer 3; Miles Inc., Elkhart, IN). The IL-10 level in the culture supernatant was assayed using an ELISA. In brief, 96-well plates were coated with 2 tg/ml rat antimurine IL-10 (PharMigen, San Diego, CA) and blocked with 1% BSA in PBS, culture supernatant was added, and incubation was done overnight at 4°C. After washing, the plates were incubated with 2 ,g/ ml biotinylated antimurine IL-1O (PharMigen). Peroxidase-streptavidin (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD) and chromogen were sequentially added, and the color reaction was stopped with 1% SDS in PBS. The standard curve was obtained using murine IL-10 COS cell supernatant.
Immunohistochemical staining. Deparaffinized sections of graft tissue were stained with an immunoperoxidase method using a polyclonal antibody to porcine insulin (Dako Corp., Carpinteria, CA) and avidin-biotin-complex (Vector Laboratories, Burlingame, CA). The sections were counterstained in hematoxylin solution and observed afterdehydration in graded alcohol. Fresh frozen sections ofthe pancreatic tissue from Ins-IL-10 mice were stained using a monoclonal antibody to murine IL-I0 (Genzyme Corp., Cambridge, MA) and the same immunoperoxidase technique.
Double transgenic mice. Ins-IL-10 mice were intercrossed to RIP-LCMV-GP or RIP-LCMV-NP mice to derive lines positive for both transgenes (IL-I0/GP and IL-I0/NP). RIP-LCMV-GP and RIP-LCMV-NP breeding mice were selected among those maintained on repeated crossing to C57BL/6. Fl mice were screened for the presence of both transgenes by PCR amplification of genomic DNA. 3-4-moold double transgenic mice and their littermates were infected with 2 x 105 plaque-forming units of LCMV Armstrong strain. Mice were eyebled monthly for the determination ofglucose level using Glucometer 3. Mice showing blood glucose levels > 300 mg/dl were killed for islet histology (Fig. I B) .
Statistical analysis. Gehan Rejection offetalpancreata or adult isletsfrom Ins-IL-10 mice by MHC-incompatible recipients. To study the potential of IL-10 to modify the islet allograft response, we initially performed grafts of fetal pancreatic tissue. Previous studies have demonstrated that after engraftment offetal pancreatic tissue, the exocrine tissue atrophies, but the endocrine cells mature into islets indistinguishable from adult islets in -3 wk ( 12). IL-10-transgenic and nontransgenic fetal pancreata from six litters were transplanted under the kidney capsule of allogeneic C57BL/6 and syngeneic BALB/c mice. 1 wk after transplantation of transgenic fetal pancreata to C57BL/6 mice (n = 6), a mononuclear cell infiltrate was observed with formation of glandular structures. However, complete necrosis of the allograft was observed 2 wk after transplantation (n = 6) (Fig. 2  A) . Nontransgenic fetal pancreatic allografts were rejected with similar kinetics (both n = 4). Differentiation ofislets and atrophy of exocrine tissue were observed in both transgenic and nontransgenic fetal pancreatic isografts to BALB/c mice 2 wk after transplantation (both n = 2 IL-10 mice (8) (Fig. 2 B) . As judged by immunohistochemistry, insulin-containing cells were present 2 wk after the isograft of transgenic or nontransgenic fetal pancreata; however, they were absent in the transgenic and nontransgenic allografts. Although expression of the IL-10 transgene in the fetal pancreas could be expected from previous studies ( 13), we performed in situ hybridization to document the transgene expression. These studies demonstrated the expression of IL-10 in E1 8 transgenic islets, as well as that in the fetal pancreatic isografts 2 wk after transplantation (Fig. 2, C and D) . The fetal pancreas is strongly immunogenic in comparison with other fetal tissues ( 14) . Additionally, it is possible that the fetal pancreas produces lower levels ofIL-10 than adult pancreatic # cells. These factors could contribute to the observed lack of IL-10-mediated immunosuppression. Therefore, we decided to study the effect of IL-10 on the response to adult islet allografts. We isolated islets from Ins-IL-10 mice and transplanted them to C57BL/6 and BALB/c mice. Both IL-lOtransgenic (n = 2) and nontransgenic adult pancreatic islets (n = 2) were rejected 2 wk after engraftment to C57BL/6 mice (Fig. 3 A ) . Both were accepted by BALB/c mice (both n = 1 ). As in the fetal transgenic pancreas grafts, there was a mononuclear cell infiltrate around, but not within transplanted IL-10-transgenic islets (Fig. 3 B) . Furthermore, in situ hybridization studies demonstrated that IL-10 was expressed in isografts 2 wk after transplantation at levels comparable to that observed in pancreatic islets of Ins-IL-10 mice (Fig. 3 C) . lk~I Since C57BL/6 mice respond quite vigorously to BALB/c tissue, we tested the ability of IL-10 to modify the islet allograft response to a strain combination that was more closely related genetically and antigenically. We chose BALB.H-2k congenic mice as recipients, since these mice share the same minor antigens with the BALB/c donor and would thus be more similar. We transplanted islets isolated from Ins-IL-10 mice into BALB.H-2k mice under the kidney capsule. Both IL-I O-transgenic (n = 2) and nontransgenic adult islets (n = 2) were rejected 2 wk after transplantation with similar histopathology as those grafted to C57BL/6 mice.
Development ofdiabetes in LCMV-infected IL-JO/GP and IL-JO/NP mice. We assessed the ability of IL-10 to protect pancreatic islets from destruction in a transgenic model where immune sensitization to islets occurs as a cross-reaction with viral antigens after LCMV infection (9) . We crossed IL-10-transgenic mice with RIP-LCMV-GP and RIP-LCMV-NP A t.', . ,. We studied the histopathology of the pancreas in the LCMV-infected and uninfected double transgenic mice. Histological examination of the pancreata from infected IL-I 0/GP and IL-10/NP mice revealed infiltration of lymphocytes into islets, which was similar to that observed in infected -/GP or -/NP mice (Fig. 5 A) . This infiltration into the islets is in striking contrast to unmanipulated IL-10-transgenic mice or uninfected IL-I0/GP (or NP) mice showing substantial periislet inflammation but no intra-islet lesions (Fig. 5 B) . There was additionally profound infiltration of mononuclear cells in the exocrine pancreata of infected double transgenic mice, which is characteristic of Ins-IL-10 mice (8) . We also studied the pancreas from one of the uninfected spontaneously diabetic IL-I0/GP transgenic mice. The tissue section appeared to have a paucity of islets (data not shown).
Production ofIL-JIO by transgenic islets. Our results demonstrating that local IL-10 production did not inhibit islet allograft rejection or autoimmune destruction of islet tissue were quite contrary to our expectations. One possible explanation of our results was that no IL-10 was actually released from the transgenic islets. Therefore, we studied the production ofIL-10 by isolated transgenic and nontransgenic islets by measuring the levels of IL-10 accumulating in the supernatants of cultured islets from individual mouse. We found that 75 isolated islets from each of two transgenic mice produced 14.2 and 6.7 U of IL-10 after 4 d in culture, whereas there was no IL-10 produced in the culture supernatants from two nontransgenic mice. We performed additional studies localizing immunoreactive IL-10 in the transgenic pancreas. The immunohistochemical studies demonstrated the expression of IL-10 in pancreatic islets oftransgenic mice but not in islets of nontransgenic mice (Fig. 6 ). cells in vivo because dendritic cells would be the main APC involved in the initiation of allograft rejection (19, 20) . Second, immunostimulatory activities ofIL-IO might be involved. IL-10 has some immunostimulatory activities including enhanced expression of class II MHC antigens on small dense B lymphocytes and induction of cytotoxic T cell differentiation; both events might be related to allograft rejection (21, 22). Third, allosensitization at locations other than the actual graft site could be occurring. The exact location of allosensitization and the types ofcells involved in allograft rejection are not fully Figure 6 . Immunohistochemical staining of a pancreatic section from a Ins-IL-0 mouse. IL-10 immunoreactivity was observed in pancreatic islets indicating the production of IL-IO by transgenic islets at the protein level. x400.
elucidated (23, 24) . Donor and/or recipient APC may present allograft-specific antigens in locations other than the graft area that are devoid ofthe influence ofthe pancreatic IL-10. Finally, it is possible that the immune system of the host develops way(s) to circumvent or overcome prolonged suppression by IL-10 in vivo; e.g., by production of counter-regulatory cytokine(s). RIP-LCMV-GP and RIP-LCMV-NP mice have defined viral antigens expressed in pancreatic 13 cells. They do not develop spontaneous diabetes; however, they develop diabetes after systemic administration of LCMV (9) . Local production of IL-10 in the pancreas is not expected to inhibit systemic presentation of viral antigens to the host immune system. This is substantiated by a strong secondary cytotoxic T lymphocyte response of splenocytes from infected double transgenic mice to viral antigens (data not shown). However, we thought that IL-10 produced by pancreatic 13 cells might inhibit continued antigen presentation that would be necessary for perpetuation of the immune reaction to the virus antigens in pancreatic 13 cells. Additionally, the documented inhibition ofcytokine production by Thl cells after exposure to IL-10 could greatly dampen the anti-islet inflammatory response. Our results that transgenic production of IL-10 did not inhibit diabetes after virus infection suggest that APC other than macrophages in the pancreas are sufficient for the observed response or that continued antigen presentation is not necessary for the immune response toward virus antigens on the pancreatic 13 cells. However, it is also possible that the properties ofthis cytokine studied in vitro do not extrapolate well to in vivo situations because of counter-regulatory effects acting within the organism.
The apparent acceleration of diabetes in double transgenic mice compared to single transgenic littermates may be a result of several effects acting separately or together in synergy. One explanation is a storage disease effect that has been observed in other transgenic mouse models (25, 26) . A substantial portion of the cellular machinery in pancreatic a cells may be directed to the production of the two transgenic proteins that renders them more susceptible to malfunction and the development of diabetes. Our observation of spontaneous development of diabetes in two IL-1 0/GP mice supports the possibility of a storage disease effect. However, the presence of a massive lymphocytic infiltration within islets of all infected diabetic double transgenic mice with islet destruction indicates a primary role of immune destruction of a cells in the development of diabetes in infected animals. Immunostimulatory activities of IL-10, such as induction of cytotoxic T cell differentiation, may play a role in the acceleration of diabetes in double transgenic mice after LCMV infection, leading to an enhancement of immune destruction of islets (21, 22) .
Taken together, our in vivo results contrast to the immunoinhibitory activities of IL-10 observed in vitro and do not support IL-10 as an immunosuppressive agent at least in the pancreas. However, other tissues may be more responsive to this type ofmanipulation. Pancreatic tissue may have high propensity for infiltration and inflammatory cell attack because of relatively high vascularity. Our observations also do not exclude the possibility of IL-10 as a systemic immunosuppressive agent against autoimmune disorders or allograft rejection. The effects of systemic administration of IL-10 may be different from those of localized transgenic long-term production. This was exemplified by the contrasting effects of systemic administration (27) and local production of TNF-a (28, 29) , which resulted in islet protection in diabetes-prone mice and islet inflammation in transgenic mice, respectively.
